Litcius/Paper detail

Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma

Runsen Jin, Xinfeng Wang, Ruochuan Zang, Chengming Liu, Sufei Zheng, Hecheng Li, Nan Sun, Jie He

2020Cancer Letters59 citationsDOI

Topics & Concepts

Cancer researchOsimertinibCarcinogenesisAdenocarcinomaBiologyMedicineCancerInternal medicineROS1Wnt/β-catenin signaling in development and cancerCancer-related gene regulationHER2/EGFR in Cancer Research
Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma | Litcius